- Home
- ZLAB vs STEW Comparison
ZLAB vs STEW Comparison
Compare ZLAB & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZLAB | STEW |
|---|---|---|
| Founded | 2013 | 1972 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZLAB | STEW |
|---|---|---|
| Price | $17.59 | $18.39 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $57.22 | N/A |
| AVG Volume (30 Days) | ★ 827.4K | 84.5K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.44 |
| Revenue | ★ $441,629,000.00 | N/A |
| Revenue This Year | $30.20 | N/A |
| Revenue Next Year | $34.71 | N/A |
| P/E Ratio | ★ N/A | $10.34 |
| Revenue Growth | ★ 24.14 | N/A |
| 52 Week Low | $17.72 | $11.97 |
| 52 Week High | $44.34 | $14.94 |
Technical Indicators
Market Signals| Indicator | ZLAB | STEW |
|---|---|---|
| Relative Strength Index (RSI) | 17.58 | 62.54 |
| Support Level | $19.40 | $17.76 |
| Resistance Level | $18.67 | $18.20 |
| Average True Range (ATR) | 0.50 | 0.19 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 3.05 | 92.31 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.